Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4520059 | 0.83 | CYP2D6 (0.45) | MGLLALDH1A1MAPK1CYP2C19CYP2D6 | |
| SCHEMBL4523571 | 0.80 | KDM4E (0.31) | ALDH1A1KDM4EGAAGLASMN1; SMN2 | |
| SCHEMBL4530738 | 0.74 | F10 (0.35) | MGLL | |
| SCHEMBL4530741 | 0.74 | F10 (0.35) | MGLL | |
| SCHEMBL4520833 | 0.73 | ALDH1A1 (0.31) | ALDH1A1MAPK1CYP2C19CYP2D6 | |
| SCHEMBL4526902 | 0.71 | F10 (0.42) | — | |
| SCHEMBL4521281 | 0.71 | F10 (0.42) | — | |
| SCHEMBL14344926 | 0.69 | MGLL (0.38) | MGLLALDH1A1CYP2D6 | |
| SCHEMBL4527683 | 0.68 | SIGMAR1 (0.42) | MGLLALDH1A1MAPK1CYP2C19CYP2D6 | |
| SCHEMBL4520507 | 0.65 | SMN1; SMN2 (0.33) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090076015-A1 | Tricyclic Spiro Compound Comprising Acyl Group Bound to Nitrogen Atom in the Ring | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-03-19 | — | — | US | disclosed |
| EP-1864984-A1 | TRICYCLIC SPIRO COMPOUND COMPRISING ACYL GROUP BOUND TO NITROGEN ATOM IN THE RING | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076015-A1 | Tricyclic Spiro Compound Comprising Acyl Group Bound to Nitrogen Atom in the Ring | KCNH1, SCN1A, SCN10A | MGLL 4624/4885ALDH1A1 2791/4885KDM4E 2297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.